Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3420 - Mouse clinical trials of pancreatic cancer: Integration of PDX models with genomics to improve patient outcomes to chemotherapeutics


10 Oct 2016


Poster display


Angela Davies


Annals of Oncology (2016) 27 (6): 526-544. 10.1093/annonc/mdw392


A. Davies1, M. Hidalgo2, J. Stebbing3, D. Ciznadija4, A. Katz4, D. Sidransky5

Author affiliations

  • 1 Medical Affairs, Champions Oncology, 07601 - Hackensack/US
  • 2 Ciocc, Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, 28050 - Madrid/ES
  • 3 Surgery And Cancer, Imperial College London - Hammersmith Hospital, London/GB
  • 4 Translational Oncology, Champions Oncology, 07601 - Hackensack/US
  • 5 Medicine, Johns Hopkins Hospital, Baltimore/US


Abstract 3420


Although a number of treatments are available for pancreatic cancer, these are often administered in prescribed sequences, which may not represent the optimal therapeutic strategy. Technologies enabling multiple regimens to be evaluated simultaneously to identify beneficial therapies are needed. Drug screening in patient-derived xenografts (PDXs) is a potential solution. We examined whether pancreatic PDXs capture patient responses to different drugs and report performance metrics highlighting clinical utility.


Pancreatic tumors from 94 patients were engrafted into immunodeficient mice to generate PDX models. Of these, 19 models were sequenced to identify key genomic alterations with therapeutic implications. Sensitivity to different therapeutics was evaluated and effects on tumor growth aligned to clinical RECIST criteria. A total of 16 PDX screening outcomes were correlated with individual clinical responses and statistical parameters such as sensitivity, specificity, and predictive values calculated.


Of the 94 implanted pancreatic tumors, 82 have completed the implantation process, with 72 (88%) successfully engrafting. Sequencing revealed alterations in 451 common genes, including those informing treatment choices such as EGFR, KRAS, and BRCA 1/2. PDX models from 39 patients were screened in 144 drug tests employing 56 FDA-approved therapies and 9 experimental agents. In 14/16 (88%) cases with available data, a correlation between clinical and PDX outcomes was noted and from this cohort we calculated positive and negative predictive values of 82% and 100% respectively.


Using a small cohort, we showed drug responses in pancreatic PDX model correlate with clinical outcomes to the same therapy. Application of such models to guide treatment decisions for pancreatic cancer patients may help lead to better outcomes. Moreover, given the clinical relevance of these models, they could also be deployed as real-time patient surrogates during drug development and clinical trials, permitting real-time analysis of treatment responses and identification of biomarkers that predict different therapeutic outcomes.

Clinical trial identification

Legal entity responsible for the study



Champions Oncology


A. Davies, D. Ciznadija: Employee of Champions Oncology Stockholder in Champions Oncology. M. Hidalgo, J. Stebbing: Advisory board for Champions Oncology. A. Katz: Employee of Champions Oncology Stockholder of Champions Oncology. D. Sidransky: Chairman of Board for Champions Oncology Stockholder in Champions Oncology.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings